Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-921 in healthy male volunteers
NCT03013881Phase 1Completed
- Sponsor
- United BioPharma
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of coprelotamab in HER2-positive breast cancer (5 arms), sponsored by United BioPharma. Primary endpoints: Adverse event incidence at 63 days and Pharmacokinetics. Started Mar 2018; status: completed.
02
Drugs
coprelotamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03013881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013881.